Pricing Log in Create free account
Sunday 18 October 2026 Export THMO’s income statement to Excel — free account

ThermoGenesis Holdings, Inc.

THMO Healthcare Medical Devices

ThermoGenesis Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $9.4 million, down 9.90% from fiscal 2022. Operating cash flow growth for three consecutive years.

0.00 0.00 NaN
Market cap
$1.1M
P/E
0.0×
Fwd P/E
5.5×
Dividend yield
—
F-score
3/9
Altman Z
−37.75
Beneish M
−9.50
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 12.82%

Capital & Financial Ratios $m

Market Cap 1.11
Revenue 9.61
Net Income (15.74)
Free Cash Flow (4.59)
Net Debt (1.18)
Current Ratio 0.52 (below 1: weak)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E 5.50
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 78.73% (at or above 15%: strong)
Next Y EPS Growth 101.84% (at or above 15%: strong)
Next Y revenue growth 182.69% (at or above 10%: strong)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.8×, against a ten-year median of 0.9×; over the ten years it ranged from 0.2× in 2016 to 3.4× in 2020.
EV/Sales against its own 10 years 48.88%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2021 2022 2023 Q'24
Cash 7 4 2 1
Receivables 1 2 1 1
Inventory 5 3 1 1
Other — — — —
15 11 5 4
2021 2022 2023 Q'24
Payables 1 1 1 1
ST’ Debt — — — —
Other 1 1 1 1
6 12 12 8

Compound Annual Growth %

10y 5y 3y
Sales (5.16%) (0.47%) (1.03%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 3 — — — —
’23 3 2 2 2 9
’22 3 3 2 3 10
’21 2 2 3 2 9
’20 3 2 2 2 10
’19 3 4 4 2 13
’18 2 2 3 3 10
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) — — — —
’23 (1) (1) 0 (2) (4)
’22 (4) (1) (1) (1) (7)
’21 (4) (1) (1) 0 (7)
’20 (3) (6) (3) (3) (14)
’19 (2) 0 (1) 0 (3)
’18 (2) (4) (1) 0 (7)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) — — — —
’23 (1) (1) 0 (2) (5)
’22 (4) (1) (1) (1) (8)
’21 (4) (1) (1) 0 (7)
’20 (3) (6) (3) (3) (14)
’19 (2) (1) (1) 0 (3)
’18 (2) (5) (1) 0 (8)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.46) — — — —
’23 (4.07) (0.91) (1.44) (2.33) (7.59)
’22 (7.21) (9.01) (4.50) (0.10) (20.45)
’21 (9.46) (17.12) (6.76) (9.91) (43.24)
’20 (50.00) (45.95) (16.67) (10.81) (117.12)
’19 (36.04) (21.17) (35.13) (62.78) (151.35)
’18 (121.62) (779.28) (54.05) (67.57) (972.97)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Trend 2024e 2025e 2026e
Price, $
Price, $ Low — — 737.10 1,179.00 94.50 105.75 73.35 43.46 2.67 0.51

Analyst estimates 2024–2026

Powerpack
High — — 3,325.50 2,898.00 1,764.00 315.00 638.10 200.25 55.35 6.67
People
People Employees — — 89 70 53 50 41 40 41 25
Revenue/emp, $m — — 0.00 0.00 0.18 0.26 0.24 0.23 0.26 0.38
Income, $m
Income, $m Revenue — — 12 12 10 13 10 9 10 9
Gross margin, % — — 23.00 35.84 22.67 43.66 12.92 37.58 25.85 20.44
EBT — — (19) (10) (46) (10) (17) (12) (12) (19)
EBT margin, % — — (155.82) (83.29) (472.19) (77.40) (172.53) (127.82) (112.68) (200.31)
Net income — — (19) 0 (41) (10) (17) (12) (12) (19)
Depreciation — — 1 0 2 3 6 4 4 9
Per share, $
Per share, $ Revenue — — 48.57 534.49 236.48 207.75 69.90 35.46 19.03 3.99
Earnings — — (75.70) (202.50) (972.97) (151.35) (117.12) (43.24) (20.45) (7.59)
Cash flow — — (39.19) (147.42) (170.73) (51.91) (103.25) (25.26) (13.22) (1.57)
Capex — — 0.00 0.00 (30.27) (2.90) (0.16) (0.35) (0.73) (0.73)
Free cash flow — — (39.19) (147.42) (201.00) (54.81) (103.41) (25.61) (13.94) (2.30)
Book value — — 131.40 1,476.09 164.57 14.59 42.11 12.96 6.03 (1.51)
Shares, m — — 0 0 0 0 0 0 1 2
Valuation, ×
Valuation, × P/E — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — 2.34 2.23 0.51 0.95 1.35 1.28 0.19 0.14
P/B — — 0.97 0.93 0.73 13.57 2.23 3.51 0.59 0.00
EV/Sales — — 2.17 2.46 0.38 1.01 1.29 1.49 0.67 0.91
EV/FCF — — (1.96) (4.85) (0.45) (3.84) (0.87) (2.07) (0.92) (1.57)
Cash, $m
Cash, $m Operating cash flow — — (10) (3) (7) (3) (14) (7) (7) (4)
Capex — — (1) 0 (1) 0 0 0 0 (2)
Free cash flow — — (10) (3) (8) (3) (14) (7) (8) (5)
Balance, $m
Balance, $m Working capital — — 7 6 2 3 9 9 (1) (7)
Total debt — — 2 7 1 5 7 9 4 —
Net debt — — (3) 3 (1) 1 (1) 2 (4) (2)
Shareholders’ equity — — 32 33 7 1 6 3 3 (4)
Returns, %
Returns, % ROA — — (37.25) (9.31) (120.86) (63.68) (90.65) (54.82) (56.30) (117.41)
ROIC — — 0.00 0.00 (494.38) (175.04) (104.19) (84.29) 0.00 0.00
ROE — — (57.60) (14.26) (198.86) (248.38) (481.90) (245.58) (335.42) 13,773.95
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Mar 2024

Charts ten years each

ThermoGenesis Holdings, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
VJET Flyte Aviation, Inc. $2.1M — (loss-making) — (loss-making) +380.66% (above 0%: growing) n/m −26.70% (below 0%: shrinking) 9.62% (388.13%) Compare
NUWE Nuwellis, Inc. $2.0M — (loss-making) — (loss-making) +14.14% (above 0%: growing) n/m −51.55% (below 0%: shrinking) 76.08% (160.94%) Compare
AFIB Acutus Medical, Inc. $1.7M — (loss-making) — (loss-making) +204.18% (above 0%: growing) n/m +76.40% (above 0%: growing) 14.20% (3.81%) Compare
DHAI DIH Holding US, Inc. $1.6M — (loss-making) — −30.67% (below 0%: shrinking) n/m −167.90% (below 0%: shrinking) 50.33% (33.62%) Compare
DYNTQ Dynatronics Corporation $1.2M — (loss-making) — (loss-making) −7.61% (below 0%: shrinking) n/m −193.04% (below 0%: shrinking) 24.65% (1.26%) Compare
THMO ThermoGenesis Holdings, Inc. $1.1M — (loss-making) 5.5× +6.42% (above 0%: growing) n/m +62.12% (above 0%: growing) 43.92% (20.35%)
SSKN Strata Skin Sciences, Inc. $1.0M — (loss-making) — (loss-making) −2.97% (below 0%: shrinking) n/m −376.88% (below 0%: shrinking) 61.82% 7.66% Compare
FEED ENvue Medical, Inc. $950.0K — (loss-making) — (loss-making) −51.62% (below 0%: shrinking) n/m +19.75% (above 0%: growing) (111.30%) (2,290.38%) Compare
PFSA PROFUSA, Inc. $650.0K 0.0× — — n/m −359.25% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $1.4M — — −2.97% — −109.72% 37.49% (18.71%)

All 149 Medical Devices stocks →

ThermoGenesis Holdings, Inc. (THMO) key facts

  • Concern: ThermoGenesis Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $9.4 million, down 9.90% from fiscal 2022.
  • ThermoGenesis Holdings, Inc. (THMO) is a Medical Devices company in the Healthcare sector.
  • Return on equity was 13,774.0% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −37.75 (distress zone) for fiscal 2023.

Source: company filings (standardised) and stockrow calculations.

ThermoGenesis Holdings, Inc. (THMO) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/THMO · Data as of Mar 31, 2024 · For information only; not investment advice. · © 2026 stockrow.com